Vardenafil (levitra) for erectile dysfunction.
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002986:Clinical Trials as Topic; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D048909:Diabetes Complications; D003925:Diabetic Angiopathies / Q000150:complications; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D005252:Fees, Pharmaceutical; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011468:Prostatectomy / Q000009:adverse effects; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride
D004791:Enzyme Inhibitors; D007093:Imidazoles; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human